Pulmonary Aspiration of Gastric ContentsPhase 4NCT02703896
Prophylaxis for Aspiration of Gastric Contents.
A Phase 4 study testing Drug either PPIS or H2RA and prokinetics and orogastric intubation in people with Pulmonary Aspiration of Gastric Contents, run by King Saud University.
Trial summary
Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone… Read more about this study
- Who is it for?
- Ages 15 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Aspiration of Gastric Contents
- What is being tested?
- Drug either PPIS or H2RA and prokinetics and orogastric intubation
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,920 participants
- Where
- No sites listed yet
- Study dates
- Jan 2012to Dec 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 70 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- -
Who cannot join
- Patients with upper gastrointestinal disorders, Body mass index above 35 kg/m2, Receiving medicines known to effect the secretory and or motor functions of stomach, Had undergone surgery on stomach, With difficult intubation Intestinal obstruction, Partuients and Diabetes
- .
- -
About this study
Official title: "Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery.
Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone, metoclopramide and erythromycin on intragastric pH, volume and bile refluxate.
Read the detailed description
(This description is for one drug and similar for other drugs) We repacked the placebo, lansoprazole 15 mg and lansoprazole 15 mg plus domperidone 10 mg in 180 envelopes (times two) and then two envelope in one envelope each for evening and morning of the same size, shape and color and their name were changed as drug one, drug two and drug three by a person who was not taking part in the study to the patients (single-blind) and investigators (double-blind) blinded of it. The group assign paper was sealed in another envelope that was opened to know which drug corresponds to either drug one or drug two or drug three after the statistical analysis(triple-blind).
On the preoperative anaesthesia visit, a day before surgery, the nature and purpose of the study was explained to each patient. We asked each patient to pick up on one envelop from the envelopes (randomization). Thus the patients were allocated to either Group C (control), Group L lansoprazole 15 mg or Group LD lansoprazole 15 mg with domperidone 10 mg randomly by sealed envelope method. Age, sex, ASA physical status, weight, height, BMI and the study drug given were recorded for each patient. All patients also received tablet diazepam 5 mg with study drugs. These drugs were given orally with 20 ml of drinking water at 8:00 p.m. in the evening day before surgery and 6:00 a.m. morning on the day of surgery. According to the hospital policy, all patients were fasted from 12:00 midnight. Upon arrival in the receiving area of the operating room. All patients were asked if they had been aware of any unusual feeling (side effect) after taking the study drug.
In the operating room, routine monitors were attached to the patients and turned on. After pre-oxygenation with 100% O2 by face mask using eight breaths vital capacity method, anaesthesia was induced with injection fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg and rocuronium 0.6-0.9 mg/kg. Lungs were ventilated taking care not to inflate the stomach. Maintaining cricoid pressure trachea was intubated with cuffed endotracheal tube. Placement and position was confirmed with EtCO2 monitor and then secured properly. After establishing stable anaesthesia, an endotracheal tube sized 8.5 internal diameter was passed via oral route in the esophagus with anterior displacement of larynx. A predetermined length marked with adhesive tape (xiphoid process to ear lobule- fro ear lobule to nasal tip) of stomach tube sized 18 F was passed through the esophageally placed endotracheal tube. Placement of this tube within the stomach was verified with auscultation over the epigastrium during insufflation of 10-15 ml of air. Gastric contents were gently aspirated manually with 60 ml syringe by an investigator who was blind of group assignment. Applying manual pressure over the epigastrium while the patient was in supine and then left and right lateral positions, gastric tube was then manipulated to ensure maximum emptying of gastric contents. The stomach tube was then removed followed by esophageally placed endotracheal tube. Any problem encountered during inserting or removing the oro-esophageally placed endotracheal tube or gastric tube was also recorded. The volume of gastric contents was measured with graduated syringe and pH using pH meter. The pH meter was calibrated using standard buffers at pH values of 4, 7 and 9.20. This pH meter has a precision of 0.01 units over the entire pH range. A minimum of one-millimeter volume of gastric contents was sufficient for pH determination with pH meter. In case of very little amount of gastric contents, we cut the stomach tube and aspirated gastric material with disposable plastic pipette. Samples less than one-millimeter were considered as no gastric contents because a minimum of one- millimeter of gastric contents was sufficient for pH- metry. Using bile salts as marker for bile, we applied qualitative Hay's sulphur test for the presence of bile salts. A minimum volume of one millimeter of gastric contents was adequate to perform Hay's sulphur test. In this test finely powered sulphur is sprinkled on the surface of cool (17 OC or below) liquid. If bile salts are present sulphur sinks down, sooner or later, in accordance with their percentage. If bile salts are present in from 1:5,000 (0.02%or 200 mcg/ml to 1:10,000 (0.01% or 100 mcg/ml) sulphur at once begins to sink and all precipitated in two or three minutes; even in dilution of 1:120,000 (0.0008% or 8.33 mcg/ml precipitation occurs. On the other hand, if sulphur remains floating on the surface, bile salts are absent.
Anaesthesia was maintained with air, O2 and sevoflorane. Patients also received incremental doses of fentanyl and rocuronium as required. At the end of surgery, injection atropine and neostigmine were given to antagonize the residual effect of rocuronium. All patients were extubated in lateral position and then transferred to recovery room.
Time since premedication T1 (time from evening dose till aspiration of gastric contents) and Time since premedicationT2 (time from morning dose till aspiration of gastric contents), pH, volume of gastric contents and results of Hay's sulphur test were also recorded for all patients.
Statistical test were performed using GraphPad Software, Inc., San Diego, United States and results are expressed as absolute values or mean ± standard deviation SD (SEM). Statistical analysis between the groups were carried out using analysis of variance (ANOVA) for age, BMI, time since premedication T1, time since NPO and T2 , pH and volume. Chi square test was applied for sex, ASA physical status, Hay's test and risk of aspiration according to criteria defined (pH ≤ 2.5 and volume ≥ 0.4ml/kg or 25 ml. Post hoc tests with Bonferrni correction applied where p-value significant(p <0,05). A p-value of less than 0.05 was considered statistically significant. Power analysis revealed that the sample size (n= 30) in each group was of the study was sufficient to detect a difference of 0.7 among the groups in gastric pH and volume at a significant level of 0.05 (=α 0 with a power of 0.85.
- Conditions
- Pulmonary Aspiration of Gastric Contents
- Being tested
- Drug either PPIS or H2RA and prokinetics, orogastric intubation
- Keywords
- g a, bile reflux. PPIs, H2RAs, prokinetic agents
- Medical subject headings
- Respiratory Aspiration of Gastric Contents
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Drug either PPIS or H2RA and prokineticsDrug
Also called Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine
Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups
- Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )
- Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)
- Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)
- Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)
- Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)
- Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)
- Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)
- Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)
- Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)
- Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
orogastric intubationProcedure or surgery
Also called OGT Insertion
OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
| Study group | Role | What they receive |
|---|---|---|
| Group C (placebo) | Placebo comparator | Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am
1. Group C (placebo)
2. Group C (placebo)
3. Group C (placebo)
4. Group C (placebo)
5. Group C (placebo)
6. Group C (placebo)
7. Group C (placebo)
8. Group C (placebo)
9. Group C (placebo)
10. Group C (placebo) Receives: Drug: Drug either PPIS or H2RA and prokinetics; Procedure: orogastric intubation |
| Either PPIs or H2RAs | Active comparator | Drug Intervention Two doses at 8.00 pm and then at 6.00 am
1. Group L (lansoprazole 15 mg)
2. Group E(esomeprazole 20 mg)
3. Group P (pantoprazole 20 mg)
4. Group R (rabeprazole 10 mg)
5. Group O (omeprazole 20 mg)
6. Group T (cimetidine 200 mg)
7. Group F (famotidine 20 mg)
8. Group N (nizatidine 150 mg)
9. Group Z (ranitidine 150 mg)
10. Group S (lafutidine 10 mg) Receives: Drug: Drug either PPIS or H2RA and prokinetics; Procedure: orogastric intubation |
| Either PPIs or H2RAs+prokinetics | Active comparator | Drug intervention Two doses at 8.00 pm and then at 6.00 am
1. Group L D (lansoprazole 15 mg+ domperidone 10 mg)
2. Group EM (esomeprazole 20 mg+metoclopramide 10 mg)
3. Group PD (pantoprazole 20 mg+domperidone 10)
4. Group RM (rabeprazole 10 mg+metoclopramide 10 mg)
5. Group OD (omeprazole 20 mg+domperidone 10)
6. Group TD (cimetidine 200 mg+domperidone 10)
7. Group FM (famotidine 20 mg+metoclopramide 10 mg)
8. Group NM (nizatidine 150 mg+metoclopramide 10 mg)
9. Group ZD (ranitidine 150 mg+ domperidone 10 mg)
10. Group SD (lafutidine 10 mg+domperidone 10 mg) Receives: Drug: Drug either PPIS or H2RA and prokinetics; Procedure: orogastric intubation |
| Either PPIs or H2RAs+Prokinetic | Active comparator | Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg ) Receives: Drug: Drug either PPIS or H2RA and prokinetics; Procedure: orogastric intubation |
| Intervention Orogastric intubation | Other | After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents. Receives: Drug: Drug either PPIS or H2RA and prokinetics; Procedure: orogastric intubation |
What is being measured
The primary outcome is the main question the study is designed to answer.
pH of gastric contents
pH was measured with pH meter. Unit whole digit with two decimal point for example, 4.24
Measured: Immediate after induction of general anaesthesia
Secondary outcomes (1)
volume of gastric contents
Measured with graduated syringe. Units milliliters (ml)
Measured: Immediate after induction of general anesthesia.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2016 (estimated)
- Study startJan 2012
- Primary completionJan 2012
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Aspiration of Gastric ContentsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,920 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Saud University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ALTAF HUSSAIN, King Saud University
- Investigators
- ALTAF HUSSAIN, FCPS,EDAIC, Principal investigator, Assistant Professor and Consultant Anaesthetist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02703896
- Sponsor's protocol ID
- 06-546
- Status last verified
- Mar 2016
- First submitted
- 28 Feb 2016
- Last updated
- 9 Mar 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery.
- ClinicalTrials.gov ID
- NCT02703896
- Acronym / sponsor ID
- 06-546
- Conditions
- Pulmonary Aspiration of Gastric Contents
- Keywords
- g a, bile reflux. PPIs, H2RAs, prokinetic agents
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,920 participants (actual)
- Lead sponsor
- King Saud UniversityUniversity, hospital or other
- Study start
- Jan 2012
- Primary completion
- Jan 2012 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 9 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone, metoclopramide and erythromycin on intragastric pH, volume and bile refluxate.
Detailed description
(This description is for one drug and similar for other drugs) We repacked the placebo, lansoprazole 15 mg and lansoprazole 15 mg plus domperidone 10 mg in 180 envelopes (times two) and then two envelope in one envelope each for evening and morning of the same size, shape and color and their name were changed as drug one, drug two and drug three by a person who was not taking part in the study to the patients (single-blind) and investigators (double-blind) blinded of it. The group assign paper was sealed in another envelope that was opened to know which drug corresponds to either drug one or drug two or drug three after the statistical analysis(triple-blind).
On the preoperative anaesthesia visit, a day before surgery, the nature and purpose of the study was explained to each patient. We asked each patient to pick up on one envelop from the envelopes (randomization). Thus the patients were allocated to either Group C (control), Group L lansoprazole 15 mg or Group LD lansoprazole 15 mg with domperidone 10 mg randomly by sealed envelope method. Age, sex, ASA physical status, weight, height, BMI and the study drug given were recorded for each patient. All patients also received tablet diazepam 5 mg with study drugs. These drugs were given orally with 20 ml of drinking water at 8:00 p.m. in the evening day before surgery and 6:00 a.m. morning on the day of surgery. According to the hospital policy, all patients were fasted from 12:00 midnight. Upon arrival in the receiving area of the operating room. All patients were asked if they had been aware of any unusual feeling (side effect) after taking the study drug.
In the operating room, routine monitors were attached to the patients and turned on. After pre-oxygenation with 100% O2 by face mask using eight breaths vital capacity method, anaesthesia was induced with injection fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg and rocuronium 0.6-0.9 mg/kg. Lungs were ventilated taking care not to inflate the stomach. Maintaining cricoid pressure trachea was intubated with cuffed endotracheal tube. Placement and position was confirmed with EtCO2 monitor and then secured properly. After establishing stable anaesthesia, an endotracheal tube sized 8.5 internal diameter was passed via oral route in the esophagus with anterior displacement of larynx. A predetermined length marked with adhesive tape (xiphoid process to ear lobule- fro ear lobule to nasal tip) of stomach tube sized 18 F was passed through the esophageally placed endotracheal tube. Placement of this tube within the stomach was verified with auscultation over the epigastrium during insufflation of 10-15 ml of air. Gastric contents were gently aspirated manually with 60 ml syringe by an investigator who was blind of group assignment. Applying manual pressure over the epigastrium while the patient was in supine and then left and right lateral positions, gastric tube was then manipulated to ensure maximum emptying of gastric contents. The stomach tube was then removed followed by esophageally placed endotracheal tube. Any problem encountered during inserting or removing the oro-esophageally placed endotracheal tube or gastric tube was also recorded. The volume of gastric contents was measured with graduated syringe and pH using pH meter. The pH meter was calibrated using standard buffers at pH values of 4, 7 and 9.20. This pH meter has a precision of 0.01 units over the entire pH range. A minimum of one-millimeter volume of gastric contents was sufficient for pH determination with pH meter. In case of very little amount of gastric contents, we cut the stomach tube and aspirated gastric material with disposable plastic pipette. Samples less than one-millimeter were considered as no gastric contents because a minimum of one- millimeter of gastric contents was sufficient for pH- metry. Using bile salts as marker for bile, we applied qualitative Hay's sulphur test for the presence of bile salts. A minimum volume of one millimeter of gastric contents was adequate to perform Hay's sulphur test. In this test finely powered sulphur is sprinkled on the surface of cool (17 OC or below) liquid. If bile salts are present sulphur sinks down, sooner or later, in accordance with their percentage. If bile salts are present in from 1:5,000 (0.02%or 200 mcg/ml to 1:10,000 (0.01% or 100 mcg/ml) sulphur at once begins to sink and all precipitated in two or three minutes; even in dilution of 1:120,000 (0.0008% or 8.33 mcg/ml precipitation occurs. On the other hand, if sulphur remains floating on the surface, bile salts are absent.
Anaesthesia was maintained with air, O2 and sevoflorane. Patients also received incremental doses of fentanyl and rocuronium as required. At the end of surgery, injection atropine and neostigmine were given to antagonize the residual effect of rocuronium. All patients were extubated in lateral position and then transferred to recovery room.
Time since premedication T1 (time from evening dose till aspiration of gastric contents) and Time since premedicationT2 (time from morning dose till aspiration of gastric contents), pH, volume of gastric contents and results of Hay's sulphur test were also recorded for all patients.
Statistical test were performed using GraphPad Software, Inc., San Diego, United States and results are expressed as absolute values or mean ± standard deviation SD (SEM). Statistical analysis between the groups were carried out using analysis of variance (ANOVA) for age, BMI, time since premedication T1, time since NPO and T2 , pH and volume. Chi square test was applied for sex, ASA physical status, Hay's test and risk of aspiration according to criteria defined (pH ≤ 2.5 and volume ≥ 0.4ml/kg or 25 ml. Post hoc tests with Bonferrni correction applied where p-value significant(p <0,05). A p-value of less than 0.05 was considered statistically significant. Power analysis revealed that the sample size (n= 30) in each group was of the study was sufficient to detect a difference of 0.7 among the groups in gastric pH and volume at a significant level of 0.05 (=α 0 with a power of 0.85.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Group C (placebo) | Placebo comparator | Drug: Drug either PPIS or H2RA and prokinetics, Procedure: orogastric intubationDrug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am 1. Group C (placebo) 2. Group C (placebo) 3. Group C (placebo) 4. Group C (placebo) 5. Group C (placebo) 6. Group C (placebo) 7. Group C (placebo) 8. Group C (placebo) 9. Group C (placebo) 10. Group C (placebo) |
| Either PPIs or H2RAs | Active comparator | Drug: Drug either PPIS or H2RA and prokinetics, Procedure: orogastric intubationDrug Intervention Two doses at 8.00 pm and then at 6.00 am 1. Group L (lansoprazole 15 mg) 2. Group E(esomeprazole 20 mg) 3. Group P (pantoprazole 20 mg) 4. Group R (rabeprazole 10 mg) 5. Group O (omeprazole 20 mg) 6. Group T (cimetidine 200 mg) 7. Group F (famotidine 20 mg) 8. Group N (nizatidine 150 mg) 9. Group Z (ranitidine 150 mg) 10. Group S (lafutidine 10 mg) |
| Either PPIs or H2RAs+prokinetics | Active comparator | Drug: Drug either PPIS or H2RA and prokinetics, Procedure: orogastric intubationDrug intervention Two doses at 8.00 pm and then at 6.00 am 1. Group L D (lansoprazole 15 mg+ domperidone 10 mg) 2. Group EM (esomeprazole 20 mg+metoclopramide 10 mg) 3. Group PD (pantoprazole 20 mg+domperidone 10) 4. Group RM (rabeprazole 10 mg+metoclopramide 10 mg) 5. Group OD (omeprazole 20 mg+domperidone 10) 6. Group TD (cimetidine 200 mg+domperidone 10) 7. Group FM (famotidine 20 mg+metoclopramide 10 mg) 8. Group NM (nizatidine 150 mg+metoclopramide 10 mg) 9. Group ZD (ranitidine 150 mg+ domperidone 10 mg) 10. Group SD (lafutidine 10 mg+domperidone 10 mg) |
| Either PPIs or H2RAs+Prokinetic | Active comparator | Drug: Drug either PPIS or H2RA and prokinetics, Procedure: orogastric intubationDrug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg ) |
| Intervention Orogastric intubation | Other | Drug: Drug either PPIS or H2RA and prokinetics, Procedure: orogastric intubationAfter general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents. |
Who may qualify
- Ages
- 15 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (3 listed)
- Patients with upper gastrointestinal disorders, Body mass index above 35 kg/m2, Receiving medicines known to effect the secretory and or motor functions of stomach, Had undergone surgery on stomach, With difficult intubation Intestinal obstruction, Partuients and Diabetes
- .
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Drug either PPIS or H2RA and prokineticsAlso: Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidineDrug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups 1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 ) 2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10) 3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10) 4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg) 5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10) 6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10) 7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10) 8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10) 9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10) 10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10) | Drug | Either PPIs or H2RAs, Either PPIs or H2RAs+Prokinetic, Either PPIs or H2RAs+prokinetics, Group C (placebo), Intervention Orogastric intubation |
| orogastric intubationAlso: OGT InsertionOGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia. | Procedure or surgery | Either PPIs or H2RAs, Either PPIs or H2RAs+Prokinetic, Either PPIs or H2RAs+prokinetics, Group C (placebo), Intervention Orogastric intubation |
Primary outcome
pH of gastric contents
Time frame: Immediate after induction of general anaesthesia
pH was measured with pH meter. Unit whole digit with two decimal point for example, 4.24
1 secondary outcome
volume of gastric contents
Time frame: Immediate after induction of general anesthesia.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2016.
- Individual participant dataSharing planned: Yes
Related trials for Pulmonary Aspiration of Gastric Contents
Recruiting
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
Pulmonary Aspiration
Enrolling by invitationObservational study
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists
Recruiting
Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists
Residual Gastric Contents, Pulmonary Aspiration of Gastric Contents
Active, not recruiting
Sonographic Assessment of Cricoid Pressure
Aspiration; Gastric Contents, Anesthesia, Intubation Complication
RecruitingObservational study
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
Anesthesia, Sedation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ALTAF HUSSAIN, FCPS,EDAIC principal investigator
Assistant Professor and Consultant Anaesthetist
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Drug either PPIS or H2RA and prokinetics and orogastric intubation in people with Pulmonary Aspiration of Gastric Contents, run by King Saud University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pH of gastric contents (time frame: Immediate after induction of general anaesthesia). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2016.